Re: Wells et al.: Aflibercept, Bevacizumab, or Ranibizumab for diabetic macular edema: Two-year results from a comparative effectiveness randomized clinical trial (Ophthalmology 2016;123:1351-1358)
Physicians are taught it is important to temper initial enthusiasm with the test of time. This lesson was illustrated in the paper by Wells et al.1 The 1-year post hoc analysis showed that, for the group of eyes presenting with diabetic macular edema (DME) with worse than 20/40 visual acuity, aflibercept was superior to ranibizumab and bevacizumab; however, this article, which evaluates the 2-year data, indicates there is no difference in visual outcomes between aflibercept and ranibizumab. The authors also point out that the small relative differences in visual acuity at 2 years, among all three drugs, raises the questions whether differences observed at 2 years are clinically relevant.
Source: Ophthalmology - Category: Opthalmology Authors: Paul Tornambe Tags: Correspondence Source Type: research
More News: Avastin | Clinical Trials | Diabetes | Endocrinology | Eyes | Lessons | Lucentis | Opthalmology | Ranibizumab Injection